ViaCyte Inc. has secured $20 million through a deal with Janssen Research & Development as it prepares to launch clinical studies of a regenerative-medicine treatment for Type 1 diabetes.In Type 1 diabetes, the pancreas produces little or no insulin. This forces patients to take insulin by injection. ViaCyte's product is an implant that could reduce or eliminate the need for daily insulin injections....
Endocrinology | Researchers at Princeton University have devised a new method to measure glucose levels that requires only a beam of light and the palm of a hand, according to research published in Biomedical Optics Express.Now working to shrink the laser system to a portable size, Sabbir Liakat, a graduate student in electrical engineering, and colleagues are hopeful the technique could provide a new
Susan M. Collins, R- Maine, released the following column:. As the founder and co-chair of the Senate Diabetes Caucus, I have learned a great deal about this devastating disease affecting nearly 29 million Americans, including some 90,000 Mainers. It costs our nation more than $245 billion annually.
Support Medicare Coverage of Continuous Glucose Monitors (CGM) Ask your Senators to co-sponsor legislation to ensure people over 65 have access to life-saving CGM today. Thousands of people are benefiting daily from tighter glucose control reached with the help of a continuous glucose monitor (CGM). However, Medicare does not currently cover CGM devices, leaving seniors […]
Today, the U.S. Food and Drug Administration allowed marketing of the first zinc transporter 8 autoantibody (ZnT8Ab) test that can help determine if a person has type 1 diabetes and not another type of diabetes. When used with other tests and patient clinical information, the test may help some people with type 1 diabetes receive timely diagnosis and treatment for their disease.